Search

Displaying results 3321 - 3330 of 4644 in total
  1. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

    Categories: Lipid Modifying Agents, Plain
  2. Drug

    Quinethazone

    go.drugbank.com/drugs/DB01325
    Approved

    Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.

  3. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age...

  4. Drug

    AGuIX

    go.drugbank.com/drugs/DB18189
    Investigational

    It is under development as a radiosensitizer to be used during radiation treatment of malignant glioma.

  5. Drug

    Bleselumab

    go.drugbank.com/drugs/DB15253
    Investigational

    Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney

  6. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  7. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).

  8. Drug

    Prothrombin

    go.drugbank.com/drugs/DB11311
    ApprovedInvestigational

    Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  9. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Human cord blood hematopoietic progenitor cells can be collected from both related or unrelated donors. … associated with reduced incidence and severity of graft versus host disease (GVHD) thus improved survival rates of transplant patients compared to allogeneic bone marrow transplant setting, which may be

  10. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function [A31484]. … Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications.